Sheppard Mullin·FDA / LIFE SCIENCES REGULATORY
FDA Issues Warning Letters to Four Peptide Sellers for Unapproved Drug Marketing
FDA's August 2026 warning letters to peptide companies signal ongoing enforcement against unapproved DTC sales while the agency simultaneously considers expanding 503A compounding access.
fda-enforcementwarning-letterspeptide-productsunapproved-drugs503a-compoundingdtc-marketingregulatory-compliance
Read the original firm alert → Wednesday, September 23, 2026